Shuttle Pharmaceuticals (NASDAQ:SHPH) Major Shareholder Buys $21,818.65 in Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt bought 6,755 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The stock was bought at an average cost of $3.23 per share, for a total transaction of $21,818.65. Following the completion of the acquisition, the insider owned 78,597 shares in the company, valued at $253,868.31. This trade represents a 9.40% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Wednesday, July 1st, Financial Lp Hrt bought 3,959 shares of Shuttle Pharmaceuticals stock. The shares were bought at an average price of $3.30 per share, for a total transaction of $13,064.70.
• On Monday, June 29th, Financial Lp Hrt purchased 25,836 shares of Shuttle Pharmaceuticals stock. The shares were bought at an average cost of $3.44 per share, with a total value of $88,875.84.

Shuttle Pharmaceuticals Stock Performance

NASDAQ:SHPH opened at $3.65 on Friday. The stock has a 50-day simple moving average of $5.69 and a two-hundred day simple moving average of $10.59. The firm has a market capitalization of $2.34 million, a PE ratio of -0.08 and a beta of 0.29. Shuttle Pharmaceuticals Holdings, Inc. has a 52-week low of $2.90 and a 52-week high of $55.90.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.60 EPS for the quarter.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on SHPH shares. Weiss Ratings raised shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday. Wall Street Zen upgraded shares of Shuttle Pharmaceuticals to a “sell” rating in a research report on Saturday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

Institutional Investors Weigh In On Shuttle Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Connective Capital Management LLC bought a new stake in shares of Shuttle Pharmaceuticals in the 3rd quarter valued at approximately $357,000. Ikarian Capital LLC purchased a new position in shares of Shuttle Pharmaceuticals in the 4th quarter worth approximately $124,000. Boothbay Fund Management LLC bought a new position in shares of Shuttle Pharmaceuticals during the 4th quarter valued at approximately $37,000. Finally, Geode Capital Management LLC bought a new position in shares of Shuttle Pharmaceuticals during the 4th quarter valued at approximately $26,000. 4.58% of the stock is currently owned by hedge funds and other institutional investors.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .